Beraprost therapy in children with pulmonary hypertension secondary to congenital heart disease.
We present a report on children with severe pulmonary hypertension secondary to congenital heart disease who received 6 months of beraprost therapy. The children had an increase in intracardiac left-to-right shunt and a reduction of the pulmonary-to-systemic vascular resistance ratio, whereas the pulmonary artery pressure was not significantly changed.
Limsuwan
A
A
Division of Pediatric Cardiology, Ramathibodi Hospital, Mahidol University, Rama VI Road, Bangkok, 10400, Thailand. alimsuwan@yahoo.com
Pienvichit
P
P
Khowsathit
P
P
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D004541:Eisenmenger Complex / Q000188:drug therapy; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D013785:Thailand; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; C048081:beraprost; D011464:Epoprostenol